Chemicals & Small Molecules

AG14361 is a potent inhibitor of PARP1 with Ki of <5 nM. It is at least 1000-fold more potent than the benzamides. AG14361 treatment before irradiation statistically significantly increases the sensitivity to radiation therapy. AG14361 enhances the growth-inhibitory and cytotoxic effects of topoisomerase I poisons and increases the persistence of camptothecin-induced DNA single-strand breaks.

AR-42 (also known as OSU-HDAC42), a derivative of hydroxamate-tethered phenylbutyrate is a broad-spectrum deacetylase inhibitor of both histone and non-histone proteins. AR-42 treatment induces histone hyperacetylation and p21WAF/CIP1 overexpression, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells.

AR-42 (also known as OSU-HDAC42), a derivative of hydroxamate-tethered phenylbutyrate is a broad-spectrum deacetylase inhibitor of both histone and non-histone proteins. AR-42 treatment induces histone hyperacetylation and p21WAF/CIP1 overexpression, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells.

AR-42 (also known as OSU-HDAC42), a derivative of hydroxamate-tethered phenylbutyrate is a broad-spectrum deacetylase inhibitor of both histone and non-histone proteins. AR-42 treatment induces histone hyperacetylation and p21WAF/CIP1 overexpression, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells.

AZD2461 is a novel PARP inhibitor with low affinity for than Olaparib. AZD2641 is currently in Phase I clinical studies to treat solid tumors.

AZD2461 is a novel PARP inhibitor with low affinity for than Olaparib. AZD2641 is currently in Phase I clinical studies to treat solid tumors.

BAM7 is a direct and selective activator of BAX with IC50 value of 3.3 µM.

BAM7 is a direct and selective activator of BAX with IC50 value of 3.3 µM.

Belinostat, also known as PXD101, is a novel and potent hydroxamate-type HDAC inhibitor.